- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Theradiag Partners with Biogaran on Infliximab Biosimilar Monitoring Kits in France
Last week, Theradiag, a French company specializing in in vitro diagnostics and theranostics (targeted therapy based on findings in diagnostic tests) announced that it has entered a new partnership agreement with pharmaceutical group Biogaran.
Last week, Theradiag, a French company specializing in in vitro diagnostics and theranostics (targeted therapy based on findings in diagnostic tests) announced that it has entered a new partnership agreement with pharmaceutical group Biogaran.
Biogaran is a French pharmaceutical group that specializes in generics. In 2014, Biogaran Biosimilars was created, and in February the following year, Celltrion’s biosimilar infliximab (marketed in the European Union as Remsima) was launched in France by Biogaran.
Through this agreement, Biogaran will offer its Lisa Tracker monitoring kits throughout France to support the biosimilar, and Theradiag will handle implementation, provide training to laboratories, and provide clinician support concerning drug monitoring.
The Lisa Tracker kits are used to monitor patients taking anti-tumor necrosis factor (anti-TNF) treatments for various chronic inflammatory diseases. The kit allows clinicians to monitor patient’s trough plasma levels of circulating tumor necrosis factor (TNF), anti-TNF drug levels, and levels of anti-drug antibodies. The combination of these measurements allows physicians to better optimize the patient’s treatment.
In November 2017, Theradiag announced a similar partnership with another pharmaceutical company, Biogen, to provide the Lisa Tracker kits to its patients treated with another infliximab biosimilar, Flixabi, in France and other European nations.
“Together with our partnerships with Janssen, MSD, Pfizer, and Biogen, this deal with Biogaran will enable us to supply our Lisa Tracker kits with all the infliximabs in the market and also for other monoclonal antibodies. It’s also very good news for doctors and their patients, as it will facilitate more personalized therapies,” said Michel Finance, Theradiag’s CEO.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
